Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hedy Teppler

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Annals of Surgery|February 1, 2003
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trialJoseph S Solomkin, Albert E Yellin, Ori D Rotstein, et al.
AIDS Research and Human Retroviruses|June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE StudyEdward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Lack of a significant drug interaction between raltegravir and tenofovirLarissa A Wenning, Evan J Friedman, James T Kost, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Annals of Surgery|February 1, 2003
Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trialJoseph S Solomkin, Albert E Yellin, Ori D Rotstein, et al.
AIDS Research and Human Retroviruses|June 28, 2016
Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE StudyEdward P Lam, Cecilia L Moore, Eduardo Gotuzzo, et al.
The Journal of Infectious Diseases|May 10, 2002
Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267David A Wohl, Francesca T Aweeka, John Schmitz, et al.
Journal of the Pediatric Infectious Diseases Society|November 20, 2015
Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of AgeSharon Nachman, Carmelita Alvero, Edward P Acosta, et al.
Antimicrobial Agents and Chemotherapy|July 16, 2008
Lack of a significant drug interaction between raltegravir and tenofovirLarissa A Wenning, Evan J Friedman, James T Kost, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|November 30, 2006
Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individualsMartin Markowitz, Javier O Morales-Ramirez, Bach-Yen Nguyen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 14, 2020
Impact of Low Birth Weight and Prematurity on Neonatal Raltegravir Pharmacokinetics: Impaact P1097Diana F Clarke, Jos Lommerse, Edward P Acosta, et al.
Pageof 7